Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism.

Alexander T CohenAmol D DhamaneXuejun LiuRisho SinghStella HanRobert StellhornJane WangXuemei Luo

Published in: Journal of the National Comprehensive Cancer Network : JNCCN (2024)

Extended anticoagulation treatment of ≥3 months with apixaban was associated with lower rates of recurrent VTE, MB, and CRNMB compared with LMWH in adults with cancer-associated VTE.

Keyphrases

venous thromboembolism
direct oral anticoagulants
atrial fibrillation
combination therapy
growth factor
replacement therapy